FOLH1 and prostate cancer: Kratochwil et al. reported a prostate-specific membrane antigen (PSMA)-targeted α-radiation therapy (225Ac-PSMA-617) which induced complete remission in prostate cancer patients (including decreasing PSA levels to less than 0.1 ng/mL) without hematologic toxicity [29].